New oral drug EP395 tested for COPD safety
NCT ID NCT05572333
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial investigates the safety and tolerability of EP395, an oral capsule taken once daily for 12 weeks, in people with chronic obstructive pulmonary disease (COPD). The study includes 61 adults aged 45 and older and compares EP395 against a placebo. Researchers monitor side effects, vital signs, lab values, and heart activity to determine if the drug is safe enough for further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EP395
What this could lead to
If successful, EP395 could offer a new oral treatment option to help manage COPD symptoms and inflammation.
What could go wrong
This is an early-phase trial focused on safety, not effectiveness. The drug may not improve COPD outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bradford Royal Infirmary, Clinical Research Facility
Bradford, BD9 6RJ, United Kingdom
-
IKF Pneumologie GmbH & Co. KG
Frankfurt, 60596, Germany
-
IKF Pneumologie GmbH & Co. KG Institut für klinische Forschung Pneumologie
Mainz, 55128, Germany
-
Medicines Evaluation Unit Ltd. (MEU)
Manchester, M23 9QZ, United Kingdom
-
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
Großhansdorf, 22927, Germany
-
Southampton University Faculty of Medicine
Southampton, SO16 6YD, United Kingdom